Przejdź do zawartości
Merck

Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Bioorganic & medicinal chemistry letters (2018-05-20)
Matthew W Martin, Jennifer Y Lee, David R Lancia, Pui Yee Ng, Bingsong Han, Jennifer R Thomason, Maureen S Lynes, C Gary Marshall, Chiara Conti, Alan Collis, Monica Alvarez Morales, Kshama Doshi, Aleksandra Rudnitskaya, Lili Yao, Xiaozhang Zheng
ABSTRAKT

N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its potential use as a therapeutic target for oncology and inflammation indications.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
FT895, ≥98% (HPLC)